Table 1.
Characteristics of LGGs in the training and validation cohorts
| Characteristics | Training dataset | Validation dataset | P |
|---|---|---|---|
| Age (year) | 42.54 ± 13.66 | 43.64 ± 12.53 | 0.3570 |
| KPS | 86.51 ± 12.22 | 86.8 ± 13.87 | 0.4491 |
| Gender | 0.7086 | ||
| Female | 175 (44.5%) | 61 (46.9%) | |
| Male | 218 (55.5%) | 69 (53.1%) | |
| Histological_type | 0.9071 | ||
| Astrocytoma | 146 (49.7%) | 50 (51%) | |
| Oligodendroglioma | 148 (50.3%) | 48 (49%) | |
| WHO_grade | 0.2414 | ||
| WHO grade 2 | 197 (50.1%) | 57 (44.2%) | |
| WHO grade 3 | 196 (49.9%) | 72 (55.8%) | |
| Seizure_history | 0.6963 | ||
| Yes | 230 (62.2%) | 77 (64.7%) | |
| No | 140 (37.8%) | 42 (35.3%) | |
| Sample_type | 0.5339 | ||
| Primary tumor | 381 (96.9%) | 128 (98.5%) | |
| Recurrent tumor | 12 (3.1%) | 2 (1.5%) | |
| IDH_status | 0.1918 | ||
| Wildtype | 75 (19.9%) | 18 (14.2%) | |
| Mutant | 302 (80.1%) | 109 (85.8%) | |
| Preoperative_antiseizure | 0.7701 | ||
| Yes | 201 (70%) | 63 (72.4%) | |
| No | 86 (30%) | 24 (27.6%) | |
| Preoperative_corticosteroids | 0.7680 | ||
| Yes | 162 (57%) | 53 (59.6%) | |
| No | 122 (43%) | 36 (40.4%) | |
| Headache_history | 0.4482 | ||
| Yes | 137 (38.2%) | 38 (33.6%) | |
| No | 222 (61.8%) | 75 (66.4%) | |
| Motor_changes | 0.8413 | ||
| Yes | 84 (23.9%) | 29 (25.4%) | |
| No | 267 (76.1%) | 85 (74.6%) | |
| Sensory_changes | 0.4837 | ||
| Yes | 65 (18.5%) | 17 (15%) | |
| No | 286 (81.5%) | 96 (85%) |